It should be noted that the aforementioned proteins that impact cytokine production (e.g. DGK, DHX37, NR2F6, etc.)can alternatively be categorized as immune checkpoint inhibitors, and disrupting them along with other inhibitors, such as PD-1 and CTLA-4, may antagonize tumor resistance more efficiently. The gene discussed is NR2F6; the disease is neoplasm.